Merck buys Idenix for $3.85 billion

Merck announced it will buy biotechnology company Idenix for $24.50 per share in cash, with the "Squawk on the Street" crew. Jim Cramer explains why he wasn't eyeing phase 2 data closely enough.
02:32
Mon, Jun 9 20149:06 AM EST